Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952194 | 0.78 | LMNA (0.52) | TSHRRAB9ALMNA | |
| SCHEMBL29957168 | 0.78 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL2736635 | 0.78 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL29957244 | 0.75 | HRH1 (0.50) | HTR2ATAAR1HRH1TDP1LMNA | |
| SCHEMBL7882222 | 0.69 | DPP4 (0.43) | HTR2ATAAR1HRH1DPP4F2 | |
| SCHEMBL3564463 | 0.69 | DPP4 (0.43) | HTR2ATAAR1HRH1DPP4F2 | |
| SCHEMBL9838705 | 0.67 | HTR2A (0.58) | HTR2ATAAR1HRH1TDP1CHRNB2 | |
| SCHEMBL3290730 | 0.67 | HRH1 (0.68) | HTR2ATAAR1HRH1TDP1DPP4 | |
| SCHEMBL13171205 | 0.67 | LMNA (0.50) | HTR2ATAAR1HRH1TDP1LMNA | |
| SCHEMBL844862 | 0.65 | HRH1 (0.65) | HTR2ATAAR1HRH1TDP1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| EP-1294699-B1 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921547-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | GENZYME | 2006-08-03 | — | — | US | disclosed |
| US-7034031-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-6969728-B2 | Antiinflammatory agents | GENZYME CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| EP-1294699-A2 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | disclosed |
| WO-2001087849-A2 | MODULATORS OF TNF- ALPHA SIGNALING | GENZYME CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | HTR2A 1056/4885TAAR1 893/4885HRH1 219/4885 |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | TNF, TNFRSF1A, CD40 | HTR2A 2433/4885TAAR1 1569/4885HRH1 1087/4885 |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | HTR2A 1440/4885TAAR1 1252/4885HRH1 950/4885 |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | TNF, TNFRSF1A, TNFRSF9 | HTR2A 1440/4885TAAR1 1252/4885HRH1 950/4885 |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | HTR2A 1440/4885TAAR1 1252/4885HRH1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.